Several neurotransmitters interact in the pathogenesis of schizophrenia. The first, to be implicated, in 1956, was serotonin. This followed the discovery, in Bernard Brodie\'s Laboratory of Chemical Pharmacology at the National Heart. Institute, that reserpine depleted the body\'s stores of serotonin, including in the brain.^[@ref1]^ A little later our own group found that reserpine had the same effect, on noradrenaline. This led us to dopamine. Eventually we understood that the effect, of reserpine could actually be accounted for in terms of dopamine. Rabbits treated with reserpine display catalcpsy-the maintenance of even abnormal body posture. Injection of the dopamine precursor, dopa, had a dramatic effect on both motor performance and wakefulness, proving beyond doubt that, dopamine was the main neurotransmitter involved.^[@ref2]-[@ref4]^

Early phase: dopamine agonists
==============================

Reserpine acts by blocking neurotransmitter uptake into monoaminergic nerve terminal storage sites *([Figure 1](#DialoguesClinNeurosci-8-137-g001){ref-type="fig"}).* A few years after this discovery, we discovered that chlorpromazine did not act on these stores but, on postsynaptic cell receptors-not only dopamine receptors (although it was here that the effect, was most, striking), but, also noradrenaline and serotonin receptors.^[@ref6]^ Subsequent research in many different, laboratories turned increasingly to dopamine as the most important neurotransmitter mediating the effect, of chlorpromazine, haloperidol, and similar drugs. This led to the development of selective compounds acting on dopamine receptors. However, these agents did not have the dramatic increase in clinical effect which might, have been expected.

![Cross-section through a monoaminergic nerve terminal.^[@ref5]^ COMT, catechol-O-methyl transferase; MAO, monoamine oxidase. Reproduced from reference 5: Carlsson A. Physiological and pharmacological release of monoamines in the central nervous system. In: von Euler US, Rosell S, Uvnäs B, eds. *Mechanisms of Release of Biogenic Amines.* Oxford, UK: Pergamon Press; 1966;331-346. Copyright © Pergamon Press 1966.](DialoguesClinNeurosci-8-137-g001){#DialoguesClinNeurosci-8-137-g001}

Atypical antipsychotics
=======================

The discovery of the dibenzodiazepinc clozapine led to the identification of the atypical antipsychotics, which are mixed antagonists of all three receptors (dopamine, serotonin, and noradrenaline). Their advantage was that they displayed antipsychotic activity with fewer or no extrapyramidal side effects, which was quite a novelty at the time. It became well accepted that adding antagonists acting on these other neurotransmitters improved the therapeutic profile, by decreasing extrapyramidal side effects.

When considering benzamides, we faced a rather confusing situation. Benzamides as a family displayed high selectivity for dopamine D~2~ and D~3~ receptors, yet at, least two of them, amisulpride and remoxipride, were atypical. How could a dopamine receptor-selective compound be atypical? The answer could not lie in the benzamide structure, since a modification of the benzamide molecule yielded raclopride, a typical neuroleptic. A tentative explanation was that the D~2~ receptor population was heterogeneous, despite being one and the same molecule. How could that, come about?

D~2~ receptor heterogeneity
===========================

D~2~ receptor heterogeneity was confirmed using positron emission tomography (PET) in patients who first received conventional therapy for optimal antipsychotic effect, and were then given a highly selective Dopamine D~2~ antagonist, as a labeled ligand.^[@ref8]^ Binding indices were determined in striatum and temporal cortex *([Figure 2](#DialoguesClinNeurosci-8-137-g002){ref-type="fig"}).* The resulting profiles differed markedly. In striatum, the profile was as expected: high haloperidol, and low clozapine. In temporal cortex, all profiles were high and bunched. The striatal pattern could be viewed as predicting extrapyramidal side effects, and the temporal cortex pattern as predicting antipsychotic effects.

![Binding index in striatum (left panel) and temporal cortex (right panel) of patients treated with typical and atypical antipsychotics.^[@ref8]^ Reproduced from reference 8: Xiberas X, Martinot JL, Mallet L, et al. Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. *Br J Psychiatry.* 2001;179:503-508. Copyright © Royal College of Psychiatrists 2001.](DialoguesClinNeurosci-8-137-g002){#DialoguesClinNeurosci-8-137-g002}

This study is not unique. A similar study used a different ligand and a different, technique, but. had the same outcome,^[@ref9]^ confirming the suspicion that dopamine D~2~ receptor populations in striatum and temporal cortex are not identical. There is more than one receptor subtype or subpopulation. The speculation is that, in striatum the population is dominated by synaptically located receptors whereas in temporal cortex the dominant, receptor subtype is extrasynaptic.

Dopamine D~2~ receptors are located at dopaminergic synapses, as well as extrasynaptically *([Figure 3](#DialoguesClinNeurosci-8-137-g003){ref-type="fig"}).* Dopamine concentrations are proportional to their proximity to the synapse, highest, being closest. Some receptors-the autore ceptors, which have long been recognized-are extrasy naptic and located on the dopaminergic neuron itself. All have a tremendous capacity for up and downregulation according to the variations in dopamine concentration at. the different, sites. Extrasynaptic receptors are known to be much more responsive than postsynaptic receptors. Thus, receptor heterogeneity is reflected by synaptic versus extrasynaptic receptors. Yet despite the dichotomy, a form of continuity prevails.

![Electron micrograph of a dopaminergic nerve terminal. (1) Synaptic receptors; (2) and (3) extrasynaptic receptors; (4) dopamine transporter. Red: highest dopamine concentration (near synapse).^[@ref10]^ Reproduced from reference 10: Sesack SR. Synaptology of dopamine neurons. In: Di Chiara G, ed. *Dopamine in the CNS. Vol 1.* Berlin: Springer-Verlag; 2002:63-120. Copyright © Springer-Verlag 2002.](DialoguesClinNeurosci-8-137-g003){#DialoguesClinNeurosci-8-137-g003}

Partial dopamine agonists
=========================

In the 1980s we became interested in (-)-3-(3-hydroxyphcnyl)-N-n-propylpipcridine (3-PPP, prcclamol) which has an asymmetric carbon: (+)-3-PPP behaves as a full agonist, displaying a biphasic curve, first inhibiting then stimulating animal locomotor activity, much like apomorphinc *([Figure 4](#DialoguesClinNeurosci-8-137-g004){ref-type="fig"}).* This is due at least in part to the greater sensitivity of autoreceptors: when autoreceptors are stimulated, the dopaminergic system is inhibited by negative feedback. As the dose increases, postsynaptic receptors take over and the system becomes stimulated. The (-)enantiomer, on the other hand, is only a partial agonist, meaning that it. has an agonist effect on the highly responsive autoreceptors but an antagonistic effect on postsynaptic receptors (although achieving some stimulation in the absence of dopamine). This intrinsic activity explains why 3-PPP exhibits not, only antipsychotic^[@ref12]^ but, also antiparkinsonian properties.^[@ref13]^

![Effect of (+)- and (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP) on rat locomotor activity, sc, subcutaneous.](DialoguesClinNeurosci-8-137-g004){#DialoguesClinNeurosci-8-137-g004}

*[Figure 5](#DialoguesClinNeurosci-8-137-g005){ref-type="fig"}* illustrates the differences between the effect, of antagonists and partial agonists on motor activation. A partial agonist will act, as an inhibitor in the presence of high dopamine activity and as a stimulant in the presence of ver}\' low dopamine activity. The two activities meet at a level which represents the drug\'s intrinsic activity. A partial agonist can thus be described as a "dopamine stabilizer." In contrast, a pure antagonist, will inhibit to zero irrespective of the initial activity level, leading to catalepsy. A partial agonist, can thus act as an antipsychotic if it, has sufficiently low intrinsic activity. In schizophrenics (-)-3-PPP was an active antipsychotic but became ineffective after more than 1 week of treatment.^[@ref13]^ The suggested explanation was that, its intrinsic activity was too high, making the autoreceptors subsensitive. It, was therefore predicted that agents with lower intrinsic activity would have sustained antipsychotic activity. This proved to be precisely the case with aripiprazole, which was shown to be an effective antipsychotic with almost no extrapyramidal side effects. It also induced a slight but, significant decrease in prolactin. This is the profile expected of a partial dopamine receptor agonist.

![Effect on psychomotor activation of partial agonists (right panel) versus pure antagonists (left panel).^[@ref11]^ Reproduced from reference 11: Hjorth S, Carlsson A, Clark D, et al. Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP. *Psychopharmacology.* 1983;81:89-99. Copyright © Springer-Verlag 1983.](DialoguesClinNeurosci-8-137-g005){#DialoguesClinNeurosci-8-137-g005}

Dopamine stabilizers (or partial antagonists)
=============================================

Surprisingly, we found dopamine stabilizers that were similar to partial agonists, yet which proved to have zero intrinsic activity when tested on dopamine receptors in vivo (for review, see ref 14). Their zero intrinsic activity was particularly puzzling. One such compound, the substituted phenylpiperidine (-)-OSU6162,has a somewhat, similar pattern of psychomotor activation to the partial agonist (-)-3-PPP *(Figure 5).* It, is also quite similar in structure. Yet it is not, a partial agonist. This and a related compound, ACR16, bind to the receptors but, show low affinity for dopamine D~2~ receptors in vitro.

The effect of ACR16 was compared with that, of haloperidol on in vivo displacement in rats of raclopride, a dopamine D~2~ receptor antagonist, *([Figure 6](#DialoguesClinNeurosci-8-137-g006){ref-type="fig"}).* The doseresponse curve with ACR16 was much shallower, and it was impossible to determine when it. would have reached zero. This points to a subpopulation of dopamine D2 receptors that is available to haloperidol but less avail ablc-and perhaps not available at all-to dopamine stabilizers. These compounds are dopamine receptor antagonists, able to displace at dopamine receptors, but. not to the same extent as haloperidol.

![Striatal in vivo occupancy studies: displacement of ^3H^radopride binding by ACR16 and haloperidol. (Reprinted with the permission of M. Rigby, Merck Pharmaceuticals, West Dayton, Middlesex, UK).](DialoguesClinNeurosci-8-137-g006){#DialoguesClinNeurosci-8-137-g006}

We suggest, that it is the extrasynaptic subpopulation of dopamine receptors that is available to these compounds, and that the synaptic subpopulation is less readily available. Insofar as synaptic function is responsible for basic dopamine activity, stabilizers have an insufficient impact on the dopamine system to produce extrapyramidal side effects and the cognitive repercussions of hypodopaminergia.The receptors that gear up dopamine function to an extent sufficient, to produce psychosis are proposed to be predominantly extrasynaptic. Because partial dopamine antagonists can reach extrasynaptic receptors, including the autoreceptors but, not synaptic receptors, they can exert antipsychotic activity while simultaneously protecting the synapse. In summary, the hypothetical mechanism of action of dopamine stabilizers or partial antagonists in psychosis is that they preferentially inhibit extrasynaptic dopaminergic transmission while leaving synaptic transmission and basic dopamine function essentially intact.

Clinical deployment, of these compounds remains largely experimental. Both have displayed documented antipsychotic activity and have been studied to similar degrees in small clinical groups. Short-term studies have shown (-)-OSU6162 to be an effective antipsychotic and antidyskinetic. Long-term studies remain to be performed. ACR16 has been found to be safe in phase I studies in healthy volunteers and has shown promising results in early phase II studies in patients with schizophrenia, Parkinson\'s disease, and Huntington\'s disease. In schizophrenic patients, add-on ACR16 significantly decreased Positive and Negative Syndrome Scale (PANSS) ratings after 2 weeks versus no effect with placebo *([Figure 7](#DialoguesClinNeurosci-8-137-g007){ref-type="fig"}).* Dyskinesia was significantly reduced with both compounds. In advanced Parkinson\'s disease, (-)-OSU6162 decreased dyskinesia without, impairing voluntary movement (which actually improved). A similar result, was obtained with ACR16. (See ref 14 for references of preliminary reports).

![ACR16 add-on trial in schizophrenia. Valid rating total Positive and Negative Syndrome Scale (PNSS) scores (means and SD). The bars show the number of patients. (Data from a Swedish multicenter study under the direction of Professor Leif Lindström, Psychiatric Research Unit, Västerås Hospital, Västerås, Sweden).](DialoguesClinNeurosci-8-137-g007){#DialoguesClinNeurosci-8-137-g007}

Our hypothesis is that, dopaminergic receptor heterogeneity accounts for the mechanism of antipsychotic action:

-   Typical antipsychotics inhibit both extrasynaptic and synaptic transmission, thereby exerting antipsychotic activity, but. also worsening primary negative symptoms and cognitive dysfunction, not to mention the extrapyramidal syndrome.

-   Dopamine stabilizers inhibit, extrasynaptic transmission, but actually bolster synaptic transmission by negative feedback, leading to antipsychotic activity and improvement in primary negative symptoms and cognition.

-   Atypical antipsychotics, eg, clozapine, occupy an intermediate position, with a profile that can be explained possibly not only in terms of serotonin or noradrenaline receptors, but, still in terms of dopamine receptors.

A dopaminergic deficit hypothesis of schizophrenia
==================================================

The concept of extrasynaptic versus synaptic dopaminergic transmission provides the basis for turning the previous hypothesis of dopamine involvement in schizophrenia on its head, into a dopaminergic deficit hypothesis. We suggest that, for unelucidated developmental and/or biochemical reason(s), dopaminergic synapses are defective in schizophrenia, leading to feedback activation and the resulting observed increase in dopaminergic tone *([Figure 8](#DialoguesClinNeurosci-8-137-g008){ref-type="fig"}).* Hypertonicity spills over onto extrasynaptic transmission, to compensate for the deficiency in synaptic transmission (which could, if not remedied, produce negative symptoms). We propose that it, is this compensatory, poorly controlled increase in extrasynaptic transmission that is partly responsible for positive psychotic symptoms, since feedback is only effective and well-controlled where synaptic transmission is concerned. As for negative symptoms and cognitive deficit, we believe that, these result, from poor compensation for the synaptic defect.

![Updated dopaminergic deficit hypothesis: dopamine synapse in normal subjects (left) and schizophrenics (right), showing synaptic (white) and extrasynaptic (violet) transmission and feedback loop.^[@ref15]^ Reproduced from reference 15: Carlsson A, Carlsson ML. Dopaminergic stabilisers. *Adv Schizophrenia and Clin Psychiatry.* 2005;1:118-128. Copyright © Remedica 2005.](DialoguesClinNeurosci-8-137-g008){#DialoguesClinNeurosci-8-137-g008}

This hypothesis would not, replace, but, would rather add to, the already existing hypothesis for the pathophysiology of schizophrenia, given the probable heterogeneity of this disorder.
